ADVERTISEMENT

Stay up to date every week with the european biotechnology newsletter.

✕
This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent

Stay up to date every week with the european biotechnology newsletter.

Log in here to read the desired article.

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent
go to the article

go back to the homepage

  • Subscription
  • Newsletter
  • Advertise
European Biotechnology Magazine
biocom_logo
  • Latest news
  • Background
  • Opinion
  • The Mag
    • Issues
    • Special
    • Corporate publications
    • Subscribe
  • Euro Biotech Guide
  • Market Place
    • Products
    • Sponsored Publications
    • Advertise
  • Associations
  • Service
    • Newsletter
    • Contact Us
    • Editorial Team
  • Events
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

ADVERTISEMENT

red light wrosswalk
clinical trial

AstraZeneca and Ionis miss in key ATTR-CM trial

AstraZeneca and Ionis have suffered a major late-stage setback after Wainua/Wainzua (eplontersen) failed to hit the primary endpoint in a phase 3 trial in transthyretin-mediated amyloid cardiomyopathy … more ➔

goodbye sign on a desk
licensing

GSK ends Alector neuroscience deal after trial failures

GSK has pulled out of its neuroscience collaboration with Alector, ending a 2021 alliance that began with a $700m upfront payment but has since been hit by two clinical setbacks. more ➔

ADVERTISEMENT

british pounds coins
fundraising

Alchemab extends Series A with £25m from British Business Bank

Cambridge-based Alchemab Therapeutics has added £25m (€29m) to its Series A financing, taking the round to £109m (€128m) and giving the UK biotech fresh capital to advance its AI-enabled antibody … more ➔

AstraZeneca in Shanghai
licensing

AZ buys ex-China rights to Sino’s COPD drug for $2.1bn

AstraZeneca has moved to strengthen its respiratory pipeline with a late-stage Chinese COPD asset, striking a deal that gives it a lower-cost shot at a market MSD recently entered through its $10bn Verona … more ➔

sheeps grazing grass
licensing

Boehringer licenses PVT virus platform for cancer vaccines

Boehringer Ingelheim has licensed oncology rights to Prime Vector Technologies’ (PVT) Orf virus platform to develop a new generation of cancer vaccines. more ➔

European Biotechnology

1 / 4
EBM 2026_cover

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

Get a free sample copy | Abo
2 / 4
10/3/26 mw: Satz, PDF an JE, danach zu Andi

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo
3 / 4
EB425_Cover

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo
4 / 4
EB325_cover

Investors are showing enormous interest in the topic of longevity, as well as in combating chronic diseases. This is because these diseases have a negative impact on life expectancy. The USA and China … more ➔

Get a free sample copy | Abo

ADVERTISEMENT

© AI
european-biotechnology-logo

NEWSLETTER


Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.


Subscribe to our free newsletter!Subscribe here

Graph Therapeutics' team.
Start-up

Graph Therapeutics raises $5m to advance I&I pipeline

Austria’s Graph Therapeutics has raised $5m in new financing, bringing its total funding to more than $10m as it advances internal drug discovery programmes in inflammation and immunology built on … more ➔

marble sculpture hermes
fundraising

EG 427 rebrands as Cyllene and cashes in €33m Series C

French gene therapy biotech EG 427 has rebranded as Cyllene Therapeutics and raised €33m in a Series C round to push its lead neuro-urology candidate EG110A toward late-stage clinical testing. more ➔

ADVERTISEMENT

Sponsored Publications

indivumed_beide_960x540-705x397
Indivumed

Indivumed, ready to set sail to the clinic

With the separation from the biobank service business, Hamburg-based Indivumed has repositioned itself as a therapeutics biotech. Its earlier work remains the core of its medical knowledge and the … more ➔

APPOINTMENTS

all appointments

EB.com_Russell-thomasSymeres
Symeres/Axxam

One CSO for two companies

With the appointment of Russell Thomas as Chief Scientific Officer, Symeres and Axxam are further strengthening their strategic collaboration. …
more ➔

EB.com_Olav_Hellebo_neuExonate, Ltd.
Exonate Ltd.

Experienced CEO takes over

By appointing Olav Hellebø as Chief Executive Officer, biotechnology company Exonate Ltd. aims to accelerate the clinical development …
more ➔

Reb.com_Rezon_Bio_Ralf OttoRezon Bio
Rezon Bio

Biotechnology expert joins CDMO

Dr Ralf Otto, a former manager at Boehringer Ingelheim and Rentschler, has been appointed as the new Chief Operating Officer of the …
more ➔

tk.de_Immunic-CEO_Erik_LundgrenImmunic AG
Immunic

MS expert takes the helm

Erik Lundgren assumed his role as the new CEO of Immunic. He succeeds Dr Daniel Vitt, who will continue to oversee the biotech company’s …
more ➔

Scripta co-founder Peter HamleyScripta Therapeutics
Opinion

Where will AI actually move the needle in drug discovery?

Biotech’s biggest opportunity is not simply to generate more compounds faster, but to improve the biological hypotheses behind them and help focused companies turn shared datasets, better models and … more ➔

ADVERTISEMENT

novartis-logo-banting-1-vertical
M&A

Novartis buys UK ADC biotech Myricx Bio in up to $1.5bn deal

Novartis has agreed to acquire UK-based Myricx Bio for up to $1.5bn, adding a preclinical antibody-drug conjugate platform built around a novel payload class for solid tumours. more ➔

breast cancer awareness day
licensing

Genentech signs $490m breast cancer deal with Astex

Roche’s Genentech has signed an oncology research deal with Astex, hoping the UK-based biotech will hit the jackpot again after a similar tie-up with rival Novartis produced the blockbuster breast … more ➔

All news
newsletter_link

EVENT


European Biotech Magazine 960x540px
July 21 - July 23in Amsterdam, Netherlands

Join the only Neoantigen-Specific Summit this July

The 9th International Neoantigen Summit returns to Amsterdam to bring together the only dedicated forum for end-end neoantigen development. From validation and identification to clinical readouts, biomarker strategy, personalised and off-the-shelf approaches – this is your only platform dedicated to sharing critical developments in neoantigen the ... ➔

Knowbio GmbH
  • Link to LinkedIn
  • Link to Instagram
  • Contact
  • Imprint
  • Privacy policy
Scroll to top Scroll to top Scroll to top